Display options
Cite
Mauch E, Kornhuber HH, Krapf H, et al. Treatment of multiple sclerosis with mitoxantrone. Eur Arch Psychiatry Clin Neurosci. 1992;242(2):96-102doi: 10.1007/BF02191555.
Mauch, E., Kornhuber, H. H., Krapf, H., Fetzer, U., & Laufen, H. (1992). Treatment of multiple sclerosis with mitoxantrone. European archives of psychiatry and clinical neuroscience, 242(2), 96-102. https://doi.org/10.1007/BF02191555
Mauch, E, et al. "Treatment of multiple sclerosis with mitoxantrone." European archives of psychiatry and clinical neuroscience vol. 242,2 (1992): 96-102. doi: https://doi.org/10.1007/BF02191555
Mauch E, Kornhuber HH, Krapf H, Fetzer U, Laufen H. Treatment of multiple sclerosis with mitoxantrone. Eur Arch Psychiatry Clin Neurosci. 1992;242(2):96-102. doi: 10.1007/BF02191555. PMID: 1486115.
Copy Download .nbib Format: NLM
Share it on

Eur Arch Psychiatry Clin Neurosci. 1992;242(2):96-102. doi: 10.1007/BF02191555.

Treatment of multiple sclerosis with mitoxantrone.

European archives of psychiatry and clinical neuroscience

E Mauch, H H Kornhuber, H Krapf, U Fetzer, H Laufen

Affiliations

  1. Department of Neurology, Ulm University, Dietenbronn/Schwend, Federal Republic of Germany.

PMID: 1486115 DOI: 10.1007/BF02191555

Abstract

Ten multiple sclerosis patients, all with a rapid deteriorating disease profile, were treated with 12 mg/m2 of the cytostatic agent mitoxantrone, administered every 3 months. This dosage is only 25% of what a patient with a solid tumour would normally receive during the same time period. In all treated patients the deterioration was stopped following the initial dosage; in four out of ten patients there was even an immediate improvement of the neurological status. Eight out of nine patients showed an improvement after 1 year as compared with their enrollment status; the other one remained stabile. In correlation with the clinical improvement, the mean P100 latencies of visual evoked potentials showed a reduction after 1 year. However, the changes identified through magnetic resonance imaging were even clearer than those seen clinically. At admission, this group of patients presented with a total of 169 gadolinium (Gd)-enhancing lesions. Only 10 lesions were enhancing in nine patients 12 months after the initiation of treatment. It appears that mitoxantrone accelerates the disappearance of Gd-enhancing lesions and prevents the development of new ones. Minimal side effects such as mild nausea and a slight faintness were evident in six patients and then for only 1-2 days.

Cited by

References

  1. Clin Immunol Immunopathol. 1986 Aug;40(2):236-43 - PubMed
  2. J Immunol. 1986 Jul 15;137(2):727-32 - PubMed
  3. Brain. 1988 Aug;111 ( Pt 4):927-39 - PubMed
  4. Neurology. 1990 Apr;40(4):591-5 - PubMed
  5. J Neurol Neurosurg Psychiatry. 1991 Aug;54(8):683-8 - PubMed
  6. Clin Immunol Immunopathol. 1987 Oct;45(1):122-8 - PubMed
  7. Lancet. 1991 Feb 23;337(8739):441-6 - PubMed
  8. Clin Immunol Immunopathol. 1985 Apr;35(1):35-42 - PubMed
  9. Radiology. 1988 Oct;169(1):117-22 - PubMed
  10. J Immunol. 1986 Apr 15;136(8):2747-54 - PubMed
  11. J Neurol Neurosurg Psychiatry. 1989 Jan;52(1):14-7 - PubMed
  12. Ann Neurol. 1991 May;29(5):548-55 - PubMed
  13. Brain. 1990 Dec;113 ( Pt 6):1597-628 - PubMed
  14. Ann Neurol. 1983 Mar;13(3):227-31 - PubMed
  15. Arch Neurol. 1991 Oct;48(10):1011-2 - PubMed

Substances

MeSH terms

Publication Types

LinkOut - more resources